^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MLL mutation

i
Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
Phase 1
Kura Oncology, Inc.
Recruiting
Last update posted :
05/16/2024
Initiation :
07/18/2023
Primary completion :
05/01/2026
Completion :
05/01/2027
NPM1 • KMT2A
|
NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
|
Venclexta (venetoclax) • azacitidine • daunorubicin • ziftomenib (KO-539)
Phase 1
Kura Oncology, Inc.
Recruiting
Last update posted :
05/15/2024
Initiation :
02/22/2024
Primary completion :
08/01/2026
Completion :
08/01/2027
FLT3 • NPM1 • KMT2A
|
FLT3 mutation • NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
|
cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • ziftomenib (KO-539) • fludarabine IV
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/12/2024
Initiation :
11/10/2024
Primary completion :
12/31/2027
Completion :
12/31/2027
FLT3 • NPM1 • KMT2A
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL rearrangement • FLT3 wild-type • MLL mutation
|
daunorubicin • revumenib (SNDX-5613) • Starasid (cytarabine ocfosfate)
Phase 1/2
BioNova Pharmaceuticals (Shanghai) LTD.
Recruiting
Last update posted :
02/21/2024
Initiation :
09/16/2023
Primary completion :
06/01/2026
Completion :
06/01/2027
NPM1 • KMT2A
|
NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
11/21/2023
Initiation :
08/23/2016
Primary completion :
11/20/2023
Completion :
11/20/2023
TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1
|
TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation
|
cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous
Phase 3
Acute Leukemia French Association
Withdrawn
Last update posted :
12/30/2015
Initiation :
04/01/2010
Primary completion :
04/01/2016
FLT3
|
MLL mutation
|
cytarabine • azacitidine • idarubicin hydrochloride • Vesanoid (tretinoin)